ALG 000111
Alternative Names: ALG-000111Latest Information Update: 12 Aug 2021
Price :
$50 *
At a glance
- Originator Aligos Therapeutics
- Class Antivirals; Small molecules
- Mechanism of Action Capsid protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 23 Jun 2021 Updated pharmacodynamics from preclinical studies in Hepatitis B presented at the International Liver Congress 2021 (ILC-2021)
- 21 Jun 2021 Preclinical trials in Hepatitis B in USA (PO)
- 21 Jun 2021 Pharmacodynamics and pharmacokinetics data from preclinical studies in Hepatitis B presented at the European Association for the Study of the Liver (EASL) Digital International Liver Congress™ 2021 (ILC 2021)